Efficacy of thrombolytic therapy in pulmonary embolism determined by MION-enhanced MRA: An experimental study in rabbits

Investigative Radiology

Volumn 33, Issue 12, 1998, Pages 853-857

  Frank, Herbert ^a,b   Loewe, Robert ^a   Loewe, Christian ^a   Oberhuber, Georg ^b   Schwaighofer, Bernhard ^c   Huber, Kurt ^a   Weissleder, Ralph ^d  

^a Division of Cardiology   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c Evangelisches Krankenhaus Vienna   (Austria)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Animal study; Contrast enhancement; Magnetic resonance (MR); MR angiography; Pulmonary embolism; Thrombolysis

Indexed keywords

ALTEPLASE; HEPARIN; HEPARIN SANDOZ; MONOCRYSTALLINE IRON OXIDE NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DIAGNOSTIC ACCURACY; FIBRINOLYTIC THERAPY; LUNG EMBOLISM; MAGNETIC RESONANCE ANGIOGRAPHY; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0032470984     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-199812000-00002     Document Type: Article

References (29)

1. Goldhaber SZ, Kessler CM, Heit JA, et al. Randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988;ii:293-298.
2. Come PC, Kim D, Parter JA, Goldhaber SZ, Braunwald E, Markis JE. Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intravenous tissue plasminogen activator. J Am Coll Cardiol 1987;10:971-978.
3. Goldhaber SZ, Kessler CM, Heit JA, et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: A randomized controlled multicenter trial. J Am Coll Cardiol 1992;20:24-30.
4. Tilsner V. Thrombolytic therapy in fulminant pulmonary thromboembolism. Thorac Cardiovasc Surg 1991;39:357-359.
5. Goldhaber SZ. Thrombolysis for pulmonary embolism. Prog Cardiovasc Dis 1991;34:113-134.
6. Werier J, Ducas J, Gu S, et al. Effect of low-molecular weight heparin on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism. Chest 1991;100:464-469.
7. Goldhaber SZ, Haire W, Feldstein M, et al. Alteplase versus heparin in acute pulmonary embolism: Randomized trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993;341:507-511.
8. Porter R, Dipalma J. Thrombolysis for pulmonary embolism. Am Fam Physician 1991;44:1365-1370.
9. Alderson P, Martin E. Pulmonary embolism: Diagnosis with multiple imaging modalities. Radiology 1987;164:297-312.
10. Woodard V, Sostman H, MacFall J, et al. Detection of pulmonary embolism: Comparison of contrast-enhanced spiral CT and time-of-ftight MR techniques. J Thorac Imaging 1995;10:59-72.
11. Falaschi F, Palla A, Formichi B, et al. CT Evaluation of chronic thromboembolic pulmonary hypertension. J Comp Assist Tomogr 1992;16:897-903.
12. Levine MN, Weitz J, Turpie AGG, et al. A new short infusion dosage regimen of recombinant tissue plasminogen activator in patients with venous thromboembolic disease. Chest 1990;97:168S-171S.
13. Bogdanov A, Weissleder R, Frank H, et al. A new macromolecule as a contrast agents for MR angiography: Preparation, properties, and animal studies. Radiology 1993;187:701-706.
14. Brasch RC. Rationale and applications for macromolecular Gd-based contrast agents. Magn Reson Med 1991;22:282-287.
15. Moseley M, White D, Wang S, Wikström M, et al. Vascular mapping using albumin-(Gd-DTPA), an intravascular MR contrast agent, and projection MR imaging. J Comp Assist Tomogr 1989;13:215-221.
16. Wang SC, Wikström M, White D, et al. Evaluation of Gd-DTPA-labeled dextran as an intravascular MR contrast agent: Imaging characteristics in normal rat tissue. Radiology 1990;175:483-488.
17. Brasch RC. New directions in the development of MR imaging contrast media. Radiology 1992;183:1-11.
18. Frank H, Weissleder R, Brady T. Enhancement of MR angiography with iron oxide: Preliminary studies in whole-blood phantom and in animals. Am J Radiol 1994;162:209-213.
19. Frank H, Bogdanov A, Schaffer B, et al. MR angiography of submillimeter vasculature with a novel intravascular contrast agent. Radiological Society of North America, 78th Scientific Assembly and Annual Meeting, Suppl. to Radiology, Book of Abstracts. Chicago, IL: Radiology, 1992:308-309.
20. Giles A. Guidelines for the use of animals in biomedical research. Thromb Haemost 1987;58:1078-84.
21. Matsuo O, Rijken DC, Collen D. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolism. Nature 1981;291:590-591.
22. Kunstlinger F, Brunelle F, Chaumont P, Doyon D. Vascular occlusive agents. Am J Radiol 1981;136:151-156.
23. Agnelli G, Buchanan M, Fernandez F, et al. A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits. Circulation 1985;72:178-182.
24. Clozel JP, Tschopp T, Luedin E, Holvoet P. Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model. Circulation 1989;79:125-133.
25. Shen T, Weissleder R, Papisov M, Bogdanov A, Brady T. Monocrystalline iron oxide nanocompounds (MION): Physicochemical properties. Magn Reson Med 1993;29:599-604.
26. Shen T, Bogdanov A, Bogdanova A, Poss K, Brady T, Weissleder R. Magnetically labeled secretin retains receptor affinity to pancreas acinar cells. Bioconj Chem 1996;7:311-316.
27. Wojta J, Turcu L, Wagner O, Korninger C, Binder B. Evaluation of fibrinolytic capacity by a combined assay system for t-PA antigen and t-PA function using monoclonal anti-t-PA antibodies. J Lab Clin Med 1987;109:665-671.
28. Wojta J, Holzer M, Hufnagl P, Christ G, Hoover R, Binder B. Hyperthermia stimulates plasminogen activator inhibitor type 1 expression in human umbilical vein endothelial cells in vitro. Am J Pathol 1991;139:911-919.
29. Huber K, Zeiner A, Beckmann R, Hornykewycz S, Laggner A, Binder B. Laboratory monitoring of thrombolytic therapy with two different dose regimens of rt-PA in acute myocardial infarction: Peak t-PA plasma levels are not related with success of therapy. Thrombos Haemost 1995;73:1327.